Business Description
Skye Bioscience Inc
NAICS : 325412
SIC : 2834
ISIN : US83086J2006
Share Class Description:
FRA:09R: Ordinary SharesTotal Employee Number:
12Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 55.01 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 45.1 | |||||
3-Year EPS without NRI Growth Rate | 39.6 | |||||
3-Year FCF Growth Rate | 42.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.43 | |||||
9-Day RSI | 45.41 | |||||
14-Day RSI | 46.02 | |||||
3-1 Month Momentum % | 14.15 | |||||
6-1 Month Momentum % | 3.42 | |||||
12-1 Month Momentum % | -83.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.78 | |||||
Quick Ratio | 1.78 | |||||
Cash Ratio | 1.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -109 | |||||
Shareholder Yield % | 4.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -173.94 | |||||
ROA % | -139.15 | |||||
ROIC % | -1550.39 | |||||
3-Year ROIIC % | 824.08 | |||||
ROC (Joel Greenblatt) % | -4367.95 | |||||
ROCE % | -173.29 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.73 | |||||
Price-to-Tangible-Book | 2.64 | |||||
EV-to-EBIT | -0.14 | |||||
EV-to-Forward-EBIT | -0.14 | |||||
EV-to-EBITDA | -0.14 | |||||
EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 3.08 | |||||
| Price-to-Net-Cash | 3.7 | |||||
Earnings Yield (Greenblatt) % | -714.29 | |||||
FCF Yield % | -172.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Skye Bioscience Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.238 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 105 | ||
| 14-Day RSI | 46.02 | ||
| 14-Day ATR (€) | 0.051849 | ||
| 20-Day SMA (€) | 0.59575 | ||
| 12-1 Month Momentum % | -83.19 | ||
| 52-Week Range (€) | 0.45 - 3.98 | ||
| Shares Outstanding (Mil) | 35.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Skye Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Skye Bioscience Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 13:30 | In 131 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| General meeting for 2026 | 2026-05-26 10:00 | 0.66 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 | 0.68 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.68 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 0.53 (+17.78%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 16:30 | 0.73 (+30.36%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 0.73 (+30.36%) |
Show
Entries
Skye Bioscience Inc Frequently Asked Questions
What is Skye Bioscience Inc(FRA:09R)'s stock price today?
The current price of FRA:09R is €0.56. The 52 week high of FRA:09R is €3.98 and 52 week low is €0.45.
When is next earnings date of Skye Bioscience Inc(FRA:09R)?
The next earnings date of Skye Bioscience Inc(FRA:09R) is 2026-08-07 Est..
Does Skye Bioscience Inc(FRA:09R) pay dividends? If so, how much?
Skye Bioscience Inc(FRA:09R) does not pay dividend.
Press Release
Articles on Skye Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers